Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19.

Nathaniel James RhodesAtheer DairemWilliam MooreAnooj ShahMichael J PostelnickMelissa E BadowskiSarah M MichienziJaime L BorkowskiRadhika S PolisettyKaren FongEmily S SpivekJames R BeardsleyCory M HaleAndrea M PallottaPavithra SrinivasLucas T Schulz

Published in: medRxiv : the preprint server for health sciences (2020)

While we observed high rates of supportive care for patients with COVID-19, we also found that ADRs were common among patients receiving drug therapy including in clinical trials. Comprehensive systems are needed to identify and mitigate ADRs associated with experimental COVID-19 therapies.

Keyphrases

coronavirus disease
sars cov
clinical trial
healthcare
palliative care
adverse drug
quality improvement
respiratory syndrome coronavirus
drug induced
emergency department
cross sectional
stem cells
mesenchymal stem cells
pain management
chronic pain
phase iii